1.120USD-3.45%Mkt Cap: 48.20M USDP/E: —Last update: 2026-05-26
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap48.20M USD
Enterprise Value46.70M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-13.06M USD
Revenue/Share—
Last Price1.120 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees—
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.53
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B-4.14
EPS (TTM)-0.34
EPS (Forward)-0.32
52W Range
0.780014% of range3.150
52W High3.150 USD
52W Low0.7800 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE126.02%
ROA-411.19%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-1.79M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-5.62%
Net Debt-1.93M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio0.24
Quick Ratio0.22
Book Value/Sh-0.2730 USD
Cash/Share0.0450 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)12.00 USD
Target Range12.00 USD – 12.00 USD
# Analysts1
Ownership
Shares Out.43.03M
Float14.04M
Insiders60.61%
Institutions12.15%
Short Interest
Short Ratio1.0d
Short % Float0.89%
Short % Out.0.35%
Shares Short147.54K
Short (prev mo.)626.32K
Technical
SMA 501.372 (-18.4%)
SMA 2001.421 (-21.2%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)36.35K
Avg Vol (10d)23.94K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—